Global Biomarkers Industry: Key Statistics and Insights in 2024-2032
Summary:
- The global biomarkers market size reached USD 79.9 Billion in 2023.
- The market is expected to reach USD 220.7 Billion by 2032, exhibiting a growth rate (CAGR) of 11.37% during 2024-2032.
- North America leads the market, accounting for the largest biomarkers market share.
- Cancer exhibits a clear dominance, driven by the rising need to identify and classify tumors into specific subtypes.
- Drug discovery and development hold the biggest share due to the increasing focus on biologically relevant targets.
- The increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and diabetes, among individuals across the globe is catalyzing the demand for biomarkers.
- The rising focus on personalized medicines, as they provide tailored medical treatment to individual patients, is impelling the market growth.
Industry Trends and Drivers:
● Advances in Technology:
Innovations assist in enabling more precise identification and validation of biomarkers. Advancements in areas like genomics and proteomics allow researchers to analyze large datasets, revealing subtle biological changes linked to diseases. Imaging technologies aid in offering non-invasive ways to detect disease biomarkers. Next- generation sequencing (NGS) and mass spectrometry assist in improving the accuracy and speed of biomarker discovery, making it easier to integrate biomarkers into clinical settings. These tools enable a deeper understanding of disease mechanisms and patient-specific factors, which is essential for developing targeted therapies.
● Rising Prevalence of Chronic Diseases:
The increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and diabetes, among individuals across the globe is catalyzing the demand for biomarkers. These conditions often require early diagnosis and precise monitoring, that biomarkers are particularly suited for. In addition, there is a rise in the need for diagnostic tools that can detect diseases at an early stage, treatment guide decisions, and monitor disease progression. Furthermore, biomarkers provide valuable insights into the molecular and cellular mechanisms of these diseases.
● Personalized Medicine:
The rising focus on personalized medicines, as they provide tailored medical treatment to individual patients, is impelling the market growth. Biomarkers provide specific information about a person’s genetic profile, disease state, and likely response to treatment. By identifying unique molecular markers, clinicians can customize therapies that are more effective and have fewer side effects for individual patients. This precision in treatment improves patient outcomes and enhances healthcare efficiency. In addition, there is an increase in the need for reliable and specific biomarkers that can guide therapeutic decisions and predict patient responses.
Request for a sample copy of this report: https://www.imarcgroup.com/biomarkers-market/requestsample
Biomarkers Market Report Segmentation:
By Product:
- Consumables
- Services
- Software
Consumables represent the largest segment as they enable early disease detection.
By Type:
- Efficacy Biomarkers
- Safety Biomarkers
- Validation Biomarkers
Safety biomarkers account for the largest market share, which can be accredited to their ability to mitigate potential risks and ensure patient safety in clinical trials.
By Disease:
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Immunological Disorders
- Renal Disorders
- Others
Cancer exhibits a clear dominance, driven by the rising need to identify and classify tumors into specific subtypes.
By Application:
- Diagnostics
- Drug Discovery and Development
- Personalized Medicine
- Others
Drug discovery and development hold the biggest share due to the increasing focus on biologically relevant targets.
By End User:
- Pharmaceutical and Biotechnology Companies
- Diagnostic and Research Laboratories
- Hospitals and Specialty Clinics
- Others
Diagnostic and research laboratories represent the largest market share on account of their ability to evaluate drug responses, assess drug metabolism, and understand the relationship between drug dose and effect.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America dominates the biomarkers market, which can be attributed to the thriving biotechnology sector.
Top Biomarkers Market Leaders:
The biomarkers market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Charles River Laboratories International Inc.
- Epigenomics AG
- Eurofins Scientific SE
- Merck KGaA
- Perkinelmer Inc.
- Qiagen N.V
- Quanterix Corporation
- SphingoTec GmbH
- Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
